GenesisCare

Ludi, Inc. Appoints Chief Commercial Officer and VP of Provider Compensation

Retrieved on: 
Tuesday, April 2, 2024
Software, Practice Management, Human Resources, Health, Hospitals, Health Technology, Professional Services, Technology, Principal, Negotiation, Software as a service, Information technology, Chlorophyll, GenesisCare, KLAS, Sunquest Information Systems, Knowledge, Banner Health, Banner, Motorola, Fair market value, Multimedia, Information system, Arena, PSAS, Management

Nashville-based Ludi, Inc., the leader in provider compensation management, today announces the appointment of Tom Arena as Chief Commercial Officer and Eric Leafgreen as Vice President of Provider Compensation.

Key Points: 
  • Nashville-based Ludi, Inc., the leader in provider compensation management, today announces the appointment of Tom Arena as Chief Commercial Officer and Eric Leafgreen as Vice President of Provider Compensation.
  • Leafgreen has nearly two decades of experience leading financial operations, provider integration and managing enterprise risk with provider arrangements.
  • He comes to Ludi from GenesisCare, an integrated oncology and multi-specialty provider network, where he was responsible for developing and negotiating provider compensation models.
  • Additionally, he advised on compensation plans, provider practice acquisitions and overall provider payment practices.

OneOncology and Coastal Cancer Center Purchase Two Radiation Oncology Centers and Partner with Three South Carolina Radiation Oncologists in Myrtle Beach and Conway

Retrieved on: 
Tuesday, February 6, 2024
Breast, Radiation, GenesisCare, Prostate, Patient, Head, Linearity, Skin, Physician, Neck, Brain, Committee, Community Oncology Alliance, Medical imaging

NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare. As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.  

Key Points: 
  • NASHVILLE, Tenn. and MYRTLE BEACH, S.C., Feb. 6, 2024 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, and its South Carolina-based partner, Coastal Cancer Center, announced they have purchased two radiation oncology centers located in Myrtle Beach and Conway, South Carolina from GenesisCare.
  • As part of the transaction, three radiation oncologists and 40 employees will join Coastal Cancer Center and continue caring for patients at both locations.
  • OneOncology and Coastal Cancer Center are purchasing two radiation oncology centers located in Myrtle Beach and Conway.
  • The Myrtle Beach radiation oncology center is located at 4708 Oleander Drive and the Conway center is at 8059 Myrtle Trace Drive.

Physician Medical Group M&A Declines in Q4:23, According to Acquisition Data from LevinPro HC

Retrieved on: 
Friday, January 12, 2024
Health care, Internal medicine, Research, Hospital, Harvest Partners, Pediatrics, Housing, Intelligence, PMG, GenesisCare, Oncology, Acquisition, McKesson Corporation, Q2:23, Physician, Pharmaceutical industry

NEW CANAAN, Conn., Jan. 12, 2024 /PRNewswire-PRWeb/ -- M&A activity in the Physician Medical Group (PMG) sector continued to decrease in Q4:23, reaching a total of 101 transactions, according to data captured in the LevinPro HC database and published by Irving Levin Associates, LLC. The fourth quarter marks the lowest activity in the PMG space all year, representing a 19% drop from Q3:23 when 125 deals were reported and a 33% decrease from Q2:23 that saw 151 acquisitions.

Key Points: 
  • M&A activity in the Physician Medical Group (PMG) sector continued to decrease in Q4:23, reaching a total of 101 transactions, according to data captured in the LevinPro HC database and published by Irving Levin Associates, LLC.
  • NEW CANAAN, Conn., Jan. 12, 2024 /PRNewswire-PRWeb/ -- M&A activity in the Physician Medical Group (PMG) sector continued to decrease in Q4:23, reaching a total of 101 transactions, according to data captured in the LevinPro HC database and published by Irving Levin Associates, LLC.
  • "With high interest rates and increased operational costs, it's not a surprise deal activity has slowed.
  • All quarterly results are published in The Health Care M&A Report, which is part of LevinPro HC, a research intelligence platform published by Irving Levin Associates, LLC.

PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 5, 2023
Patient, GenesisCare, Medicine, Ductal carcinoma, CP, RT, MBBS, DCIS, FRANZCR, Pharmaceutical industry

LAGUNA HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy (RT) in ductal carcinoma in situ (DCIS) patients in Australia.

Key Points: 
  • LAGUNA HILLS, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will present data demonstrating the decision impact on physician recommendations for radiation therapy (RT) in ductal carcinoma in situ (DCIS) patients in Australia.
  • The data will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5 - 9, 2023 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.
  • Specifically, in the interim analysis of 483-patients treated with breast conserving surgery in Australia, the use of the test resulted in a 41% change in RT recommendations and a 9% change in hormone therapy (HT) recommendations.
  • “The integration of DCISionRT into the clinical decision-making processes has a substantial impact on recommendations to personalize care and prevent over- and under-treatment,” said Dr. Yvonne Zissiadis, MBBS, FRANZCR, radiation oncologist, GenesisCare and principal investigator.

American Shared Hospital Services Enters Into Agreement to Acquire 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

Retrieved on: 
Monday, November 20, 2023
Care New England, Sales, GenesisCare, Partnership, Risk, Software, ASHS, Bankruptcy, AMS, Particle accelerator, SAN, Recurrence, Cancer, Professor, Shoe, CNE, Radiation therapy, Patient, Roger Williams Medical Center, Medical imaging

SAN FRANCISCO, CA, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ​​via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (“ASHS” or the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced that it has entered into an Investment Purchase Agreement (the “IPA”) to purchase a 60% majority equity interest in the Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, both Rhode Island limited liability companies (collectively, the “Target Companies”), as well as certain payor contracts, from GenesisCare USA, Inc., a Florida corporation (the “Seller”), for a purchase price of $2.85 million. ProspectCharterCARE, LLC d/b/a Roger Williams Medical Center and the Care New England (CNE) Health System each own 20% of the Target Companies.

Key Points: 
  • The Target Companies operate three fully functional turn-key radiation therapy cancer centers in Rhode Island, and all three sites are equipped with state-of-the-art cancer treatment technology using Linear Accelerators (LINACs) and comprehensive treatment planning software.
  • The centers are all located on or adjacent to hospital campuses and include the Southern New England Regional Cancer Centers d/b/a Maddock Radiation Therapy in Warwick, RI, and d/b/a Landmark Radiation Therapy in Woonsocket, RI.
  • The third facility is the Roger Williams Cancer Center d/b/a Roger Williams Radiation Therapy in Providence, RI.
  • These patients would have had to interrupt their life-saving treatment and attempt to seek radiation therapy elsewhere.

ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

Retrieved on: 
Thursday, December 7, 2023
Technology, Health, Oncology, Men, Health Technology, Research, Artificial Intelligence, Hospitals, Consumer, Science, Clinical Trials, Clinical trial, MMAI, Patient, GenesisCare, Medicine, Partnership, Prostate cancer, Pharmaceutical industry

The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

Key Points: 
  • The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.
  • “We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.
  • ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.
  • “Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia

Retrieved on: 
Thursday, December 7, 2023
Technology, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, Oncology, Artificial Intelligence, Other Science, Risk, Clinical trial, Principal, MMAI, Research, Patient, GenesisCare, Medicine, Partnership, Prostate cancer, Medical device

ArteraAI, the developer of multimodal artificial intelligence (MMAI)-based predictive and prognostic cancer tests, and GenesisCare , one of the leading integrated cancer care providers in Australia, today announced a partnership to help bring AI-based decision making tools to Australia as part of a new clinical trial.

Key Points: 
  • ArteraAI, the developer of multimodal artificial intelligence (MMAI)-based predictive and prognostic cancer tests, and GenesisCare , one of the leading integrated cancer care providers in Australia, today announced a partnership to help bring AI-based decision making tools to Australia as part of a new clinical trial.
  • The partnership will allow patients treated at GenesisCare clinics in Australia accelerated access to AI-based predictive and prognostic tools as part of an Australian-based clinical trial.
  • “Bringing AI-based predictive and prognostic tools to Australia as part of a new clinical trial is a vital step in fulfilling our commitment to advancing precision medicine,” said Andre Esteva, co-founder and CEO of ArteraAI.
  • “We are thrilled to partner with GenesisCare to reach more patients with localized prostate cancer and further empower shared decision-making and personalized care across the globe.”
    Professor Jarad Martin, GenesisCare Radiation Oncologist and Principal Investigator of the study, said: “Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia.

RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, October 9, 2023
Lung cancer, ASX, Safety, GenesisCare, Princess Alexandra Hospital, Patient, Pharmaceutical industry, Medical imaging, NSCLC

The dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer.

Key Points: 
  • The dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer.
  • The study will be conducted at Princess Alexandra Hospital in Brisbane, Australia, with the support of leading oncology care provider GenesisCare.
  • The technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform, which targets the PDL1 expression in NSCLC, the most common type of lung cancer.
  • Worldwide it was estimated that there are more than 2.2 million cases of lung cancer in 2020², with NSCLC accounting for approximately 85% of all lung cancer cases.

More than 50 GenesisCare locations in the U.S. now offer advanced non-surgical treatment option for patients with non-melanoma skin cancer

Retrieved on: 
Thursday, May 11, 2023
Tissue, Extremities, Radiation, Skin, Skin cancer, Cancer, MBA, Smash Mouth, Merkel-cell carcinoma, Scalp, American Society of Clinical Oncology, Journal, MD, Dermatology, Patient, GenesisCare, Risk, Melanoma, NMSC, Metastasis, Sunburn, Recurrence, VMAT, Society, Medical imaging, Dietary supplement, Pharmaceutical industry

This approach can treat multiple skin cancers at the same time, as well as areas likely to form skin cancer in the future.

Key Points: 
  • This approach can treat multiple skin cancers at the same time, as well as areas likely to form skin cancer in the future.
  • Since its launch in March 2021, more than 350 U.S. patients have benefited from the program.
  • Over 3,000 skin patients are treated annually at more than 115 GenesisCare locations across the nation, utilizing this technique as well as more traditional radiation approaches.
  • I feel super confident with my skin now that I have finished my treatment," said David Roe, a GenesisCare patient.

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Friday, April 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, MSD, Prednisolone, Oncology Drug Advisory Committee, The New England Journal of Medicine, New Drug Application, Cancer, MRK, ODAC, AstraZeneca, NEJM, Merck & Co., Prednisone, Incidence, Surgical oncology, Urology, HIV disease progression rates, Patient, Physician, Risk, GenesisCare, Propel, Mortality, BRCA, FDA, Death, News, NYSE, Food, Caregiver, Prostate cancer, Pharmaceutical industry, Medical imaging, Merck

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients, recommending against approval beyond this patient population.

Key Points: 
  • The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients, recommending against approval beyond this patient population.
  • The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer.
  • The FDA is not bound by the committee’s guidance but takes its advice into consideration.
  • AstraZeneca and Merck will continue to work with the FDA as the agency completes its review of the application.